Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for ABBV, sign up here.
Income Statement
Revenue
$54.3bn
Gross Profit
$33.9bn
Earning before Tax
$6.2bn
Net Income
$4.9bn
Net Income Common Shareholders
$4.9bn
EPS
2.73
Balance Sheet
Cash
$12.8bn
Debt
$59.4bn
Assets
$134.7bn
Liabilities
$124.3bn
Equity
$10.4bn
Enterprise Value
$321.1bn
Cash Flow Statement
Net Cash from Operations
$22.8bn
Net Cash from Investing
$-2.0bn
Net Cash from Financing
$-17.2bn
Net Cash Flow
$3.6bn
Free Cash Flow
$22.1bn
Free Cash Flow per Share
$12.48
Metrics
Price to Equity
56.26
Price to Equity (Damodaran)
56.77
Price to Book
26.41
Net Margin
0.09
Return on Equity
0.40
Return on Sales
0.15
Get immediate access to 5-years of reference grade data for ABBV for free.
Sign upAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet''s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn''s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson''s disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company Info
Industry
Drug Manufacturers - General
Employees
Address
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
Phone
847 932 7900
Website
Last Updated
2024-02-19
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.